For semi-solid and liquid manufacturing capabilities across the network, see our semi-solids and liquids services. For health and nutrition manufacturing, explore our health and nutrition services.
With more than 60 years of pharmaceutical manufacturing experience and over 20 years of CDMO expertise, NextPharma’s Limay site, operating as NextPharma SAS, is the group’s centre of excellence for high-volume non-sterile liquid and suppository production.
If you are evaluating a European CDMO partner for liquid or suppository manufacturing, discover NextPharma Limay’s core capabilities, regulatory status, facility details, and how to start a conversation with the team.
The facility is designed for high-volume manufacturing of pharmaceutical, medical device, and health and nutrition products, operating in full compliance with EU GMP standards across all product categories. Our core technology is fully traceable PLC-controlled operations, ensuring robust process control across:
Suspensions, emulsions and solutions (aqueous and alcohol-based)
Syrups and double-point ampoule
Suppositories
Alcohol-based products are handled in a dedicated Ex-Proof area. Development and industrial transfer capabilities are integrated into the site. We offer formulation development, analytical development and transfer, stability studies to ICH guidelines (zones II and IVb across five temperature/humidity conditions), scale-up, and technology transfer at NextPharma Limay, supporting projects from feasibility through to commercial manufacture.
Non-sterile liquids in bottles: High-volume production with integrated primary and secondary packaging.
Pharmaceutical ampoules: Double-point glass ampoules, including nitrogen filling and a wide range of secondary packaging solutions.
Secondary packaging for solid dosage forms: High-speed blister packaging and secondary packaging services for oral solid dosage forms with extensive know-how in handling complex pharmaceuticals products.
Suppositories and pessaries: Manufacturing and packaging with dedicated equipment and controlled heating and cooling systems.
Controlled substances: Dedicated manufacturing area and segregated storage maintained at 2 to 8°C.
Integrated analytical services: In-house HPLC systems, GC systems, atomic absorption spectrophotometry, and a fully equipped microbiology laboratory.
For semi-solid and liquid manufacturing capabilities across the network, see our semi-solids and liquids services. For health and nutrition manufacturing, explore our health and nutrition services.
Production at the NextPharma Limay site operates, amongst others, under EU GMP requirements and is routinely assessed by ANSM, ANVISA and other global regulatory agencies, as well as FDA requirements for health and nutritional products.
The site holds EcoVadis Gold certification and PSCI recognition. NextPharma Limay has been identified as part of France’s strategic industrial development initiatives and recognised as a contributor to European pharmaceutical sovereignty.
The NextPharma Limay site covers 40,000 m², with dedicated production areas and quality control laboratory facilities. Our logistics infrastructure offers more than 5,000 pallet spaces across two warehouses, including dedicated areas for cold-chain products (2 to 8°C), controlled substances, and alcohol, both operating under controlled temperature conditions (15 to 25°C). We continue to invest in expanded liquid packaging capacity as part of the site’s Industrial Master Plan. For an overview of all our sites, visit the NextPharma locations hub.
Whether it's development, manufacturing or supply. Tell us about your project and our experts will get back to you.